Study of AC-003 for steroid-resistant graft-versus-host disease
Part of Immune system & allergy clinical trials.
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell transplant from a donor (like a matched unrelated donor or a half-matched donor).
- You have been diagnosed with moderate to severe graft-versus-host disease (aGVHD) within 100 days after your transplant.
- Your aGVHD did not respond well to steroids (for example, it got worse after 3 days, didn't improve after 7 days, didn't go away after 14 days, or came back when lowering the steroid dose).
- You have not had more than one stem cell transplant, and you have not received any other treatments for aGVHD besides steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
This study is testing an investigational cell therapy called NCR102 for people who have severe graft-versus-host disease (a complication after a stem cell transplant) that mainly affects the gut and has not responded to standard treatments. The goal is to see if this new approach is safe and can help control the disease.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This study tests if a hormone called hCG can help treat moderate-to-severe graft-versus-host disease (GVHD) after a stem cell transplant. It is for adults who have recently developed GVHD and need steroids, but have not been on high-dose steroids for long.
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.